The proposed work is a proof-of-concept study in vivo for the development of a novel gene therapy for melanoma. Functionalized lipid nanoparticles can transfect melanoma cells selectively in mice, and deliver a gene that causes melanoma cells to express a-Gal, which is antigenic. This makes the melanoma cells susceptible to destruction by anti-a-Gal Ab-mediated mechanisms.
Posting date: Wed, 03/20/2024
Award start date: Mon, 04/01/2024
Award end date: Tue, 03/31/2026
